2016 Executive Compensation Schedule for NewLink Genetics Corporation Officers

Contract Categories: Human Resources › Bonus & Incentive Agreements
Summary

This document outlines the 2016 salaries, bonus targets, and equity awards for key executives of NewLink Genetics Corporation, including the Chairman, President, CFO, Vice President of Finance, and Chief Commercial Officer. It specifies each executive's base salary, bonus target as a percentage of salary, and the number of stock options and restricted stock units awarded. Performance-based restricted stock units will vest upon achieving specific company milestones, such as clinical trial results, regulatory filings, and development milestones under a collaboration agreement.

View More
EX-10.2 3 nlnk-20160107x8kxex102.htm EXHIBIT 10.2 Exhibit
Exhibit 10.2



 
2016 Salaries, Bonus Targets and Equity Awards
 
Name and Title
2016 Salary
Bonus Target*
Stock Options
Restricted Stock Unit Awards
Performance Restricted Stock Unit Awards#
 
Charles J. Link, Jr., M.D.
$659,900
70%
133,435
46,639
28,053

 
Chairman of the Board and Chief Executive and Scientific Officer
 
 
 
 
 
 
Nicholas N. Vahanian, M.D.
$574,300
50%
84,275
29,456
19,637

 
Director, President and Chief Medical Officer
 
 
 
 
 
 
John B. Henneman, III
$423,600
40%
46,351
16,201
9,819

 
Chief Financial Officer
 
 
 
 
 
 
Carl Langren
$277,500
30%
8,989
3,142
1,122

 
Vice President of Finance
 
 
 
 
 
 
Brian Wiley
$370,700
35%
18,259
6,382
7,013

 
Chief Commercial Officer
 
 
 
 
 
 
 
 
 
 
 
 
*
Bonus Targets listed as percentage of 2016 Base Salary
#
Performance Restricted Stock Unit Awards shall vest on the following schedule: (i) 50% of the shares underlying such RSU shall vest if the Company’s Phase 3 IMPRESS trial meets a statistically significant positive endpoint, (ii) 25% of the shares underlying such RSU shall vest if the Company’s NDA for Algenpantucel is accepted for filing by the FDA and (iii) 25% of the shares underlying such RSU shall vest if GDC-0919 advances into Phase 2 development and the Company receives a milestone payment related to such advancement pursuant to the terms of the License and Collaboration Agreement dated October 16, 2014 by and among the Company, NewLink Global, Genentech, Inc. and F. Hoffmann-LaRoche Ltd., as the same may be amended from time to time